Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX Stock Report

Market Cap: US$1.6b

Amylyx Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AMLX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Feb 26SellUS$227,618Justin KleeIndividual15,500US$14.69
02 Feb 26SellUS$50,516Gina MazzarielloIndividual3,448US$14.65
02 Feb 26SellUS$227,593Joshua CohenIndividual15,500US$14.68
02 Feb 26SellUS$52,097James FratesIndividual3,557US$14.65
06 Jan 26SellUS$85,589Justin KleeIndividual7,715US$11.09
06 Jan 26SellUS$85,596Joshua CohenIndividual7,715US$11.09
06 Jan 26SellUS$36,954James FratesIndividual3,326US$11.11
23 Dec 25BuyUS$100,845Karen FirestoneIndividual8,100US$12.45
01 Dec 25SellUS$94,418Camille BedrosianIndividual6,580US$14.35
30 Sep 25SellUS$175,518Camille BedrosianIndividual12,039US$14.58
30 Sep 25SellUS$128,669Gina MazzarielloIndividual8,828US$14.58
30 Sep 25SellUS$429,469Joshua CohenIndividual29,933US$15.00
30 Sep 25SellUS$154,650James FratesIndividual10,558US$14.65
30 Sep 25SellUS$430,952Justin KleeIndividual29,975US$15.01
31 Mar 25SellUS$31,954Gina MazzarielloIndividual9,192US$3.48
31 Mar 25SellUS$37,806James FratesIndividual10,896US$3.47
31 Mar 25SellUS$74,482Joshua CohenIndividual21,490US$3.47
31 Mar 25SellUS$74,454Justin KleeIndividual21,490US$3.46
31 Mar 25SellUS$43,082Camille BedrosianIndividual12,425US$3.47
20 Mar 25BuyUS$37,005Bernhardt G. ZeiherIndividual10,000US$3.70
03 Mar 25SellUS$5,022Gina MazzarielloIndividual1,611US$3.12
03 Mar 25SellUS$14,549Joshua CohenIndividual4,595US$3.17
03 Mar 25SellUS$14,483Justin KleeIndividual4,595US$3.15
24 Feb 25SellUS$13,145Gina MazzarielloIndividual4,169US$3.15

Insider Trading Volume

Insider Buying: AMLX insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of AMLX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders7,363,4796.09%
Hedge Funds12,466,82810.3%
VC/PE Firms15,196,17712.6%
Institutions85,866,97071%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.3%.

Top Shareholders

Top 25 shareholders own 85.57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.4%
FMR LLC
11,379,122US$164.9m273%0.01%
8.15%
Perceptive Advisors LLC
8,952,365US$129.7m13.3%2.89%
7.09%
BlackRock, Inc.
7,783,648US$112.8m9%no data
6.21%
Adage Capital Management, L.P.
6,816,828US$98.8m-22.5%0.15%
5.69%
TCG Crossover Management, LLC
6,243,812US$90.5m5.05%3.12%
5.29%
The Vanguard Group, Inc.
5,804,912US$84.1m10.1%no data
5.14%
Commodore Capital LP
5,650,000US$81.9m38.6%3.25%
4.19%
Saturn V Capital Management LP
4,604,878US$66.7m41.2%11.52%
3.06%
First Light Asset Management, LLC
3,355,882US$48.6m0%4.0%
2.8%
Joshua Cohen
3,079,347US$44.6m2.42%no data
2.8%
Justin Klee
3,079,280US$44.6m2.42%no data
2.55%
Point72 Asset Management, L.P.
2,801,636US$40.6m-39.9%0.07%
2.31%
Janus Henderson Group plc
2,536,233US$36.7m0%0.01%
2.2%
Driehaus Capital Management LLC
2,420,767US$35.1m91.4%0.16%
2%
Panacea Venture Management Co., Ltd.
2,200,000US$31.9m0%35.75%
1.93%
Almitas Capital LLC
2,122,597US$30.8m0%5.85%
1.73%
Morgan Stanley
1,904,226US$27.6m307%no data
1.73%
Paradigm Biocapital Advisors LP
1,900,000US$27.5m0%0.71%
1.65%
Geode Capital Management, LLC
1,812,039US$26.3m7.07%no data
1.6%
683 Capital Management, LLC
1,760,000US$25.5m-18.5%1.96%
1.55%
Great Point Partners, LLC
1,700,000US$24.6m-15%7.87%
1.48%
State Street Global Advisors, Inc.
1,621,260US$23.5m60.7%no data
1.38%
Eventide Asset Management, LLC
1,512,500US$21.9m0%0.33%
1.34%
Balyasny Asset Management L.P.
1,476,302US$21.4m0%0.04%
1.32%
Logos Global Management, L.P.
1,450,000US$21.0m0%1.52%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/04 15:07
End of Day Share Price 2026/02/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amylyx Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christopher ChenBaird
null nullBaird
Joel BeattyBaird